{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"Ventas Reports 2022 Third Quarter Results - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"TOrzuGAKuZ\"><a href=\"https:\/\/pharma-trend.com\/en\/ventas-reports-2022-third-quarter-results\/\">Ventas Reports 2022 Third Quarter Results<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/ventas-reports-2022-third-quarter-results\/embed\/#?secret=TOrzuGAKuZ\" width=\"600\" height=\"338\" title=\"&#8220;Ventas Reports 2022 Third Quarter Results&#8221; &#8212; Pharma Trend\" data-secret=\"TOrzuGAKuZ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"CHICAGO&#8211;(BUSINESS WIRE)&#8211;Ventas, Inc. (NYSE: VTR) (\u201cVentas\u201d or the \u201cCompany\u201d) today reported results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights Net Income Attributable to Common Stockholders (\u201cAttributable Net Income (Loss)\u201d) per share of $0.00 Normalized Funds from Operations* (\u201cNormalized FFO\u201d) per share of $0.76, inclusive of the benefit of approximately $20 ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20221103006233\/en\/282462\/21\/Ventas_logo.jpg"}